Jordana Joy, Associate Editor

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

The company's ONE by ONE and Biotrue Eye Care Recycling programs have collected over 84 million units or over 500,000 pounds, of used contact lenses, eye care and lens care materials in the US.

Joseph Izatt, PhD, was known for his excellence in mentorship and his work as a researcher that helped develop and advance optical coherence tomography technology, according to a news release.

Association of Schools and Colleges of Optometry President Mark Colip, OD, overviews the organization’s recent faculty report and details a new mentorship program for potential optometry students.

Catch up on what happened in optometry during the week of April 22-April 26.

The nutritional supplement comprised of a proprietary blend of lutein, zeaxanthin isomers, curcumin, and vitamin D3 improved tear production, tear film break-up time, and tear osmolarity, among others.

UC Berkeley’s Herbert Wertheim School of Optometry and Vision Science integrated the new laser in the beginning of March in its dry eye clinic for treatment of meibomian gland dysfunction.

Community Eye Care Specialists has a total of 6 locations across New York and Pennsylvania providing a variety of medical and surgical services.

The new technology, tailored to creative professionals, reduces the light that passes through the lens without reducing the color of light that is transmitted.

The IOL launch is the company’s second market debut in less than 12 months.

The World Council of Optometry partners with key optometric organizations for 2025 conference and appoints expert leaders in myopia management for education and outreach.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

Catch up on what happened in optometry during the week of April 15-April 19.

The new service, PolicyWatch, allows optometric practices and service providers as well as telemedicine solution companies to access real-time policy changes in their area of practice, spanning all 50 states and the District of Columbia.

Results from the THRIVE study found that when reading glasses were given to first-time wearers, monthly median incomes increased by 33%.

Catch up on what happened in optometry during the week of April 8-April 12.

The optometry school, founded in 1904, was the first of its kind in California.

The company selected LNZ100, designed to treat presbyopia, as its lead candidate and expects to submit an NDA in mid-2024.

The company now offers 3 different digital marketing plans for independent optometric offices, and will have a strategist dedicated to individual accounts.

Bryan Wilson, executive director of medical affairs at Genentech, details why Birmingham, Alabama was chosen as the community to study the effects of diabetic eye disease among African Americans in a new manuscript from the ADA and Genentech.

Catch up on what happened in optometry during the week of April 1-April 5.

The manuscript, "Breaking Barriers: Partnerships to Improve Diabetic Eye Health in Alabama," highlights the burden of diabetic eye disease in Alabama, as well as strategies that target racial health disparities within that population.

The trials will include patients with ocular hypertension, and assess QLS-111 in its efficacy for lowering IOP beyond levels currently achievable by targeting EVP.

The clinical stage medical technology company is developing a laser system that performs femtosecond laser image-guided high-precision trabeculomtomy, or FLigHT.

Davis Corley, CEO of Neurolens, outlines the importance a new study that show statistically significant improvement of headaches with the use of Neurolens.

Charles Leclercq, CEO of ARxVision, outlines the conception of ARxVIsion's collaboration with Seeing AI and NaviLens apps, and details the popular uses for the headset so far.

Catch up on what happened in optometry during the week of March 25-March 29.

The company, which has completed each of its CLARITY trials for both eye drops, will be reporting on their findings next month.

The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.